New patient enrollment activities resumed in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study in the third quarter of 2026New patient enrollment and treatment resumed in the
Company to hold a conference call at 8AM ET on November 5, 2026 to review results and provide a corporate updateSHELTON, Conn., Oct. 30, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the
Pathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN0) in 5 out of 7 patients (71%; 95% CI 29-96%) in the INT230-6 plus standard-of-care cohortNo invasive breast cancer
SHELTON, Conn., Sept. 8, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and
DENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock trading near
Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026Patient treatment restarted in the presurgical triple
Company to hold a conference call at 8AM ET on August 11, 2026 to review results and provide a corporate updateSHELTON, Conn., Aug. 4, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the
First patients dosed in SwitzerlandSHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company
Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancerOver 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper publishedActive strategic
Company receives the Cancer Treatment Technology Innovator of the Year awardSHELTON, Conn., May 14, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (NASDAQ:INTS) ("Intensity" or the "Company"), a
Cash and cash equivalents of $10.2 million as of March 31, 2026Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard
Company receives the Platinum Award for Innovator in Biotech Solutions CategorySHELTON, Conn., April 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (NASDAQ:INTS) ("Intensity" or the "Company"), a
Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second quarter of 2027IT-01 Study manuscript of INT230-6 used
New US patent 12,496,345 strengthens the existing portfolioPatents now granted in 41 countries protect the Company's novel intratumoral technology, including lead compound INT230-6SHELTON, Conn., March 24, 2026
Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care ("SOC") ("Cohort A") achieved a
